An important area of focus for Matrx is ensuring and improving the health of women, particularly in emerging markets where product choice is limited. Matrx’s SĀPH™, and V-Sert™ technologies for vaginal drug delivery are tailored for the management of women’s health in the treatment of infectious disease and contraceptive care.
Additional products will be forthcoming that expand the choice of Active Pharmaceutical Ingredients (API) deliverable with SĀPH™ and subsequent polymer-based technologies under development at Matrx.
We believe that in addition to the patent protection of products developed utilizing SĀPH™technology, there are significant economic and regulatory advantages associated with the Generally Recognized As Safe (GRAS) status of these excipients, allowing for a more expedient and less costly path to commercialization.
Together these development approaches extend and provide novel, patentable formulations for numerous APIs and drug delivery platforms.